Abstract:Hematopoietic cell transplantation (HCT) has now been shown to be safe and effective for selected HIV-infected patients with hematological malignancies. Autologous HCT is now the standard of care for patients with HIV-related lymphomas who otherwise meet standard transplant criteria. Limited data also support use of allogeneic HCT (alloHCT) in selected HIV-infected patients who meet standard transplant criteria. We recommend enrolling patients in clinical trials that offer access to CCR5Δ32 homozygous donors, … Show more
“…40 However, more research is needed to address several themes in HIVAM. Future trials should focus on not only testing safety and efficacy of cutting-edge immunotherapy and targeted treat ments being used in the general cancer population, but also improving the gaps in knowledge and practice for cancer screening and treatment, especially in low-resource regions.…”
Section: Discussionmentioning
confidence: 99%
“…Additional important considerations include identifying novel therapies for virally mediated tumors that disproportionally present in PLWH, treating persons with HIVAM and advanced immunosuppression, and optimizing co-management of both diseases in ART-naïve persons and those receiving care in settings where supportive therapies for hematologic toxicities and infections are limited. 40 …”
This review highlights current interventional clinical trials for HIV-associated malignancies (HIVAMs), with emphasis on 4 mechanistic areas: immunomodulatory therapies and gene therapies, including immune checkpoint inhibitors; cytotoxic therapies; novel tumor-targeted and virally targeted therapies in both AIDS-defining and non–AIDS-defining cancers (NADC); and other screening or topical/ablative interventions. A search on ClinicalTrials.gov located 35 trials, including 12 immunomodulatory or gene therapy trials, 6 cytotoxic therapy trials, 10 trials of therapies with tumor or viral molecular targets, and 7 trials evaluating screening interventions or topical or ablative therapies. Study drugs, mechanisms, and outcomes of interest, including future directions, are discussed. Targeted therapies and immunotherapies address not only the tumor but underlying viral oncogens, including possible benefits on HIV-specific immunologic control. The resulting science from the trials listed in this review will provide important translational breakthroughs for people living with HIV (PLWH) and cancer. We highlight disease-specific challenges that could be addressed in future studies, including testing the safety and efficacy of cutting-edge immunotherapy and targeted treatments used in the general cancer population, and improving gaps in knowledge and practice for cancer screening and its treatment, especially in low-resource regions. Additional important considerations include identification of novel therapies for virally mediated tumors that disproportionally present in PLWH, how to treat persons with HIVAM and advanced immunosuppression, and how to comanage both diseases in antiretroviral therapy–naïve persons and those receiving care in settings where supportive therapies for hematologic toxicities and infections are limited. Current and future clinical trials should address needs of both resource-replete and -limited regions, as well as cancers that are uncommon in or respond differently to HIV-negative populations (eg, Kaposi sarcoma or anal cancer), in addition to an increased focus on NADCs not traditionally linked with HIV, such as lung or gastrointestinal tumors.
“…40 However, more research is needed to address several themes in HIVAM. Future trials should focus on not only testing safety and efficacy of cutting-edge immunotherapy and targeted treat ments being used in the general cancer population, but also improving the gaps in knowledge and practice for cancer screening and treatment, especially in low-resource regions.…”
Section: Discussionmentioning
confidence: 99%
“…Additional important considerations include identifying novel therapies for virally mediated tumors that disproportionally present in PLWH, treating persons with HIVAM and advanced immunosuppression, and optimizing co-management of both diseases in ART-naïve persons and those receiving care in settings where supportive therapies for hematologic toxicities and infections are limited. 40 …”
This review highlights current interventional clinical trials for HIV-associated malignancies (HIVAMs), with emphasis on 4 mechanistic areas: immunomodulatory therapies and gene therapies, including immune checkpoint inhibitors; cytotoxic therapies; novel tumor-targeted and virally targeted therapies in both AIDS-defining and non–AIDS-defining cancers (NADC); and other screening or topical/ablative interventions. A search on ClinicalTrials.gov located 35 trials, including 12 immunomodulatory or gene therapy trials, 6 cytotoxic therapy trials, 10 trials of therapies with tumor or viral molecular targets, and 7 trials evaluating screening interventions or topical or ablative therapies. Study drugs, mechanisms, and outcomes of interest, including future directions, are discussed. Targeted therapies and immunotherapies address not only the tumor but underlying viral oncogens, including possible benefits on HIV-specific immunologic control. The resulting science from the trials listed in this review will provide important translational breakthroughs for people living with HIV (PLWH) and cancer. We highlight disease-specific challenges that could be addressed in future studies, including testing the safety and efficacy of cutting-edge immunotherapy and targeted treatments used in the general cancer population, and improving gaps in knowledge and practice for cancer screening and its treatment, especially in low-resource regions. Additional important considerations include identification of novel therapies for virally mediated tumors that disproportionally present in PLWH, how to treat persons with HIVAM and advanced immunosuppression, and how to comanage both diseases in antiretroviral therapy–naïve persons and those receiving care in settings where supportive therapies for hematologic toxicities and infections are limited. Current and future clinical trials should address needs of both resource-replete and -limited regions, as well as cancers that are uncommon in or respond differently to HIV-negative populations (eg, Kaposi sarcoma or anal cancer), in addition to an increased focus on NADCs not traditionally linked with HIV, such as lung or gastrointestinal tumors.
“…As in the general HIV-negative population receiving alloHSCT, malignancy relapse remained the main cause of treatment failure, with 6-month and 1-year OS were 82.4% and 58.8%, respectively [82]. Although clinical evidence for alloHSCT in PLWH is globally limited, mainly resulting from case reports and small retrospective case series, as recently reviewed elsewhere [80], alloHSCT could actually be a reasonable and potentially curative option for selected patients, with well-controlled HIV infection, who otherwise meet standard criteria for transplant eligibility [79][80][81]. Detailed information so far available from the literature on the use of alloHSCT in HIV-infected patients with AML in the ART era is summarized in Table 4 [36,37,54,[81][82][83][84][85][86][87][88][89][90][91][92][93][94][95].…”
Section: Is Allogeneic Hsct Feasible and Effective In Hiv-infected Pamentioning
confidence: 99%
“…Since the 1980s, alloHSCT has been suggested as a possible treatment option to eradicate HIV infection, but this strategy was highly unsuccessful, because HIV replication was not affected during conditioning therapy in the absence of antiviral treatment and donor lymphoid cells arising after engraftment were persistently susceptible to HIV infection [77]. Furthermore, in the pre-ART era, the survival outcomes of alloHSCT performed to treat hematological malignancies were poor, mainly due to extremely high infection-related mortality rates [78,79]. After the introduction of ART, leading to advances in HIV management, survival outcomes in PLWH undergoing alloHSCT have significantly improved, resulting similar to those obtained for subjects without HIV infection [78][79][80][81].…”
Section: Is Allogeneic Hsct Feasible and Effective In Hiv-infected Pamentioning
confidence: 99%
“…Furthermore, in the pre-ART era, the survival outcomes of alloHSCT performed to treat hematological malignancies were poor, mainly due to extremely high infection-related mortality rates [78,79]. After the introduction of ART, leading to advances in HIV management, survival outcomes in PLWH undergoing alloHSCT have significantly improved, resulting similar to those obtained for subjects without HIV infection [78][79][80][81]. Notwithstanding, there still was general reluctance to routinely use alloHSCT in PLWH, mainly because of basal immunosuppression with presumptive high risk of opportunistic infections, complex drug-drug interactions, increase in conditioning regimens-related toxicities, and risk of delayed engraftment, potentially resulting in higher transplant-related mortality (TRM) [80].…”
Section: Is Allogeneic Hsct Feasible and Effective In Hiv-infected Pamentioning
Both human immunodeficiency virus (HIV) infection and acute myeloid leukemia (AML) may be considered relatively uncommon disorders in the general population, but the precise incidence of AML in people living with HIV infection (PLWH) is uncertain. However, life expectancy of newly infected HIV-positive patients receiving anti-retroviral therapy (ART) is gradually increasing, rivaling that of age-matched HIV-negative individuals, so that the occurrence of AML is also expected to progressively increase. Even if HIV is not reported to be directly mutagenic, several indirect leukemogenic mechanisms, mainly based on bone marrow microenvironment disruption, have been proposed. Despite a well-controlled HIV infection under ART should no longer be considered per se a contraindication to intensive chemotherapeutic approaches, including allogeneic hematopoietic stem cell transplantation, in selected fit patients with AML, survival outcomes are still generally unsatisfactory. We discussed several controversial issues about pathogenesis and clinical management of AML in PLWH, but few evidence-based answers may currently be provided, due to the limited number of cases reported in the literature, mainly as case reports or small retrospective case series. Prospective multicenter clinical trials are warranted to more precisely investigate epidemiology and cytogenetic/molecular features of AML in PLWH, but also to standardize and further improve its therapeutic management.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.